October 30, 2024
2 min watch
Save
VIDEO: Longer follow-up may increase benefits of ribociclib in some patients with breast cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.
The data, presented at ESMO Congress, showed the benefit seen after patients with hormone receptor-positive, HER2-negative breast cancer were off ribociclib (Kisqali, Novartis), Tolaney told Healio in a video interview.
“I do think this 4-year data was really important for us to see so that we can see that the benefits of ribociclib are increasing with longer follow-up,” Tolaney said.
Reference:
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Tolaney reports numerous ties to industry.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.